June 2015

Varga: IHC using 22C3 Merck Ab. N=26; age 57y; all rec'd carboplatin. 69% had AE, Only 1 grade 3 AE (3.8%), no grade 4-5. #ASCO15

4:19pm June 1st 2015 via Hootsuite

Varga: Ov ca:12K new cases in US. 93% tumors have PD-1+ TILs. Phase 1b study: pembrolizumab Rx 24 mo. ORR primary end-pt. #ASCO15

4:17pm June 1st 2015 via Hootsuite

Andrea Varga (Gustave Roussy) Antitumor activity and safety of pembrolizumab in patients w/ PD-L1+ advanced ovarian cancer #ASCO15

4:14pm June 1st 2015 via Hootsuite

Bernstam: Incidental likely pathogenic muts were found in 4.3% of pts. Relative freq changes by type of tumor and gene. #ASCO15

11:16am June 1st 2015 via Hootsuite

Bernstam: 23/23 pathogenic muts confirmed by different test, 7/23 have already gone onto genetic counselling #ASCO15

11:16am June 1st 2015 via Hootsuite

Bernstam: Clinical recognition of germline pathogenic muts- BRCA1 almost all; BRCA2 only 50%. Others none. Showed #'s why not tested #ASCO15

11:15am June 1st 2015 via Hootsuite

Bernstam: ID'd likely pathogenic germline mutations: br, colon, brain, melanoma. BRCA, PTEN, TP53 (19 genes) #ASCO15

11:12am June 1st 2015 via Hootsuite

Bernstam: NCT01772771 protocol - somatic mut in archival samples. WES, RNA-Seq as rsrch smples. First 1K pts distribution shown #ASCO15

11:11am June 1st 2015 via Hootsuite

Funda Meric-Bernstam (MD Anderson) "Prevalence of incidental actionable germline mutations in 1,000 advanced cancer patients" #ASCO15

11:08am June 1st 2015 via Hootsuite

McWilliams: No change to practice, but there are up- and downsides; providers ordering tests need to be aware. Expense & pt impact #ASCO

11:08am June 1st 2015 via Hootsuite

McWilliams: 65% FP when sequencing tumor-only. Jones '15 ref http://t.co/DWI8nbO1DA Useful for high-level discussion w/germline #ASCO15

11:06am June 1st 2015 via Hootsuite

McWilliams:Even with anti-cancer Rx focus, there will be germline findings. 'We know pts have variable desires to know results' #ASCO15

11:00am June 1st 2015 via Hootsuite

Robert McWilliams (Mayo) "Interpreting Germ-Line and Somatic Mutations Together in Tumor Sequencing" Same MSKCC 1570 cases #ASCO15

10:59am June 1st 2015 via Hootsuite

Schrader: VUS a 'significant burden' downstream due to re-analysis. "Most labs need to be prepared to devote significant resources" #ASCO15

10:57am June 1st 2015 via Hootsuite

Kasmintan Schrader (MSKCC) "Tumor relevant germline findings in targeted tumor seq.: matched normal DNA of 1,570 unselected cases" #ASCO15

10:57am June 1st 2015 via Hootsuite

Garon: Some pts will decline second biopsy. T790M plasma testing is viable alternative. May come to clinic fairly soon. #ASCO15

9:43am June 1st 2015 via Hootsuite

Edward Garon (UCLA) Highlights: Non-Small Cell Metastatic Lung Cancer. EGFRi (1/2 in NEJM) http://t.co/cFAWkdZi20 Repeat biopsy #ASCO15

9:42am June 1st 2015 via Hootsuite

Polite: Coord. of care: lay navigation works, saves money, but not needed for everyone (need to target). But savings costs revenue.. #ASCO15

9:39am June 1st 2015 via Hootsuite

Polite: 'This will be the poster child' - will behavior change based on drug cost? Will the costs go down because of this? #ASCO15

9:38am June 1st 2015 via Hootsuite

Polite: Analysis of GALGB/SWOG 80405: no difference betw. Bev & Cetux. Total cost: $40K less for Bevacizumab. #ASCO15

9:36am June 1st 2015 via Hootsuite

Polite:Practices are being held accountable for drug costs - now becoming a potential cost instead of revenue source. #ASCO15

9:35am June 1st 2015 via Hootsuite

Polite: Likely overused services - range from 6% to 41%. Looked at indiv likelihood of consistently choosing - 4x to 18x more likely #ASCO15

9:29am June 1st 2015 via Hootsuite

Polite:MACRA ('doc-fix') consolidates pay-per-performance, and new payment model. Metrics: MSKCC looked Dr variation in oncology #ASCO15

9:27am June 1st 2015 via Hootsuite

Blase Polite (Univ Chicago) Health services rsrch: bridgning gap from volume-based to value. Quality, coord of care, & drug cost #ASCO15

9:23am June 1st 2015 via Hootsuite

Dreicer: Defining molecular subclass of treatment-related prostate ca:defining NEPC by epigenetic changes #ASCO15

9:16am June 1st 2015 via Hootsuite

Dreicer: STAMPEDE: docetaxel and/or zoledronic acid for hormone-naive prostate ca.10mo increase in survival. +zoledronic no improvmt #ASCO15

9:13am June 1st 2015 via Hootsuite

Robert Dreicer (U Virginia) Highlights #ASCO15 prostate ca: ADT intervention TROG trial v small #'s, not benign, known issues (osteoporesis)

9:08am June 1st 2015 via Hootsuite

O'Reilly: Non-CRC GI cancers: few practice changes . End of MET Ab targeting in EG cancers. #ASCO15

9:03am June 1st 2015 via Hootsuite

Eileen O'Reilly (MSKCC) Highlighting panc ca: PIII CONKO-005 trial, Gemcitabine +/- Erlotinib: not meaningful, no DFS OS improvmnt #ASCO15

9:02am June 1st 2015 via Hootsuite

RT @rahman_nazneen: Last cigarette: Beijing brings in smoking bans from Monday. A great decision. http://t.co/6e7JkfntjU

8:50am June 1st 2015 via Hootsuite

The strange connection between Cristiano Ronaldo and a remote dengue fever outbreak - Quartz http://t.co/lNTVIaLNOX

7:20am June 1st 2015 via Hootsuite

RT @oh_henry: Looks like we're at the peak of the hype curve re. #cancer #immunotherapy. Here's some balance: http://t.co/jXgnBcTsLk #ASCO15

6:45am June 1st 2015 via Hootsuite